DAMORA THERAPEUTICS, INC. Accrued Liabilities and Other Liabilities
DAMORA THERAPEUTICS, INC. (DMRA) had Accrued Liabilities and Other Liabilities of $8.88 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-10
- 2026-06-30: Accrued Liabilities and Other Liabilities $8.88M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $6.00M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $2.40M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $2.10M.
| Period end | Accrued Liabilities and Other Liabilities |
|---|---|
| 2026-06-30 | $8.88M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $6.00M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $2.40M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $2.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.87M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $820.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.94M 10-Q · filed 2024-11-01 |
| 2024-06-30 | $2.98M 8-K · filed 2024-10-07 |
| 2024-03-31 | $2.65M 10-Q · filed 2024-04-29 |
| 2023-12-31 | $4.13M 10-K · filed 2025-03-19 |
| 2023-09-30 | $8.08M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $9.34M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $10.51M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $7.76M 10-K · filed 2024-03-08 |
| 2022-09-30 | $6.95M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $4.67M 10-Q · filed 2022-07-29 |
| 2022-03-31 | $4.00M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $3.01M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.76M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.17M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.76M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $2.71M 10-K · filed 2022-02-17 |
| 2020-09-30 | $3.82M 10-Q · filed 2020-12-11 |
| 2019-12-31 | $4.60M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |